The NM_000152.5:c.896T>G variant in GAA is a missense variant predicted to cause substitution of Leucine by Arginine at amino acid 299 (p.Leu299Arg). This variant has been detected in 1 individual with Pompe disease. This individual was compound heterozygous for the variant and a pathogenic variant, an exon 18 deletion previously assessed by the ClinGen LSD VCEP (PMID:7603531,7717400) (PM3_Supporting). The patient with this variant had documented GAA deficiency with <30% of normal mean control level of GAA activity in cultured fibroblasts, but exact values for the patient's GAA activity and laboratory control values for GAA activity were not provided and PP4 could not be applied (PMID:7717400). This variant is absent in gnomAD v2.1.1 (PM2_Supporting). Expression of the variant in COS-7 cells resulted in <2% wild type GAA activity, indicating that this variant may impact protein function (PMID:19862843), meeting criteria for PS3_Supporting. Expression of the variant in TR4219 cells in a separate study resulted in "complete loss of GAA activity" (PMID:7717400). REVEL Score = 0.93 which is higher than the LSD VCEP threshold for PP3 (>0.7) and therefore meets this criterion. There is a ClinVar entry for this variant (Variation ID: 4025, 1 star review status) with 1 submitter classifying the variant as a Variant of Uncertain Significance. In summary, this variant meets the criteria to be classified as Likely Pathogenic for Pompe disease based on the ACMG/AMP criteria applied, as specified by the ClinGen Lysosomal Storage Disorders Variant Curation Expert panel (specifications Version 2.0): PM5, PP3, PM2_Supporting, PM3_Supporting, PS3_Supporting.